Replies to post #670548 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I agree with you completely, but even if your estimate for the cost of the EDEN was off by a factor of ten, it would be paid for by the first batch of vaccine it made.

Gary

[Roman516]

Your estimates match for Flaskworks, it appears we are on the same page.

Per my posts of 2/3/24 3:48 PM,

Each Flaskworks unit produces a batch of vaccines not just one vaccine.

"Detailed research on all the Flaskworks "EDEN" units indicate that a reputable manufacturing facility would be able to subcontract the assembly of each Flaskworks "EDEN" units, and they should have the staff capable for all the manufacturing aspects to complete each Flaskworks unit.

Detailed research on all the Flaskworks patents including the most recent "EDEN" patent indicate a modest cost bases to produce a single Flaskworks "EDEN" device, IMPO.

Example 1, a single Flaskworks "EDEN" unit at a cost of $5,000.00 each. If NWBO invest $3,000,000 to subcontract the assembly, testing and final production, they should be able to receive at least 600 Flaskworks "EDEN" units. Each Flaskworks unit is capable to produce 50 vaccines per year. So, NWBOs manufacturing partners would be able to produce approximately 30,000 vaccines per year, IMPO.

Example 2, a single Flaskworks "EDEN" unit at a cost of $10,000.00 each. If NWBO invest $3,000,000 to subcontract the assembly, testing and final production, they should be able to receive at least 300 Flaskworks "EDEN" units. Each Flaskworks unit is capable to produce 50 vaccines per year. So, NWBOs manufacturing partners would be able to produce approximately 15,000 vaccines per year, IMPO.

It appears that both examples (1, 2) would be sufficient to be able to be able to meet UK manufacture demands plus additional EU demands as well, IMPO.

Furthermore, based on MHRA approvals, NWBO would be worth more than $20 billion. Detailed S-Curve marketing and sales analysis indicates that NWBO could be worth as much as $100 billion just in the UK and EU alone. Since late 2023, Dr. Linda Liau and her UCLA team and NWBO have illustrated significant advancements with DCVax-L. The question is if global approval for DCVax-L occurs by the 4th quarter of 2024, the value of NWBO would be worth way more than $100 billion, and some estimates indicate 2X to 3X this amount. Last, consider the addition of DCVax-D also being approved, and further indications support DCVax-D capable for addressing multiple other solid tumors? The value of NWBO would be worth way more than $200 billion, $300 billion, perhaps $500 billion at the early (25% stage) of the S-Curve market and sales alone, IMPO. So, why sell NWBO short for $20 billion, IMPO. Time will tell, but it sure looks promising for NWBOs future, IMPO.
Bullish
BULLISH"